| |
Your search for [author]Abalos , RM returned 18 records. |
|
| |
Sort by:
|
|
| |
|
|
| |
|
 |
Psoriasis is characterized by altered epidermal expression of caspase 14, a novel regulator of keratinocyte terminal differentiation and barrier formation.
by Abalos , RM;
Subject: CASPASE 14; CASPASES; CELL DIFFERENTIATION; EPIDERMIS; KERATINOCYTES; PSORIASIS.
|
|
| |
|
|
|
|
| |
|
|
| |
|
|
Histochemical study of Erythema nodosum leprosum (ENL) lesions.
by Abalos , RM;
Subject: ACID PHOSPHATASE; ACUTE DISEASE; ARYLSULFATASES; BIOPSY; ERYTHEMA NODOSUM; GLYCOSAMINOGLYCANS; HISTOCYTOCHEMISTRY; HYALURONOGLUCOSAMINIDASE; LEPROSY; LIPIDS; LYSOSOMES; MONONUCLEAR PHAGOCYTE SYSTEM; NEUTROPHILS; PHOSPHOLIPIDS; SKIN; STAINING AND LABELING.
|
|
| |
|
|
|
|
| |
|
|
| |
|
|
Rapid killing of M. leprae by moxifloxacin in two patients with lepromatous leprosy.
by Pardillo , Fe Eleanor F.;
Subject: AZA COMPOUNDS; LEPROSTATIC AGENTS; LEPROSY; MICROBIAL VIABILITY; MYCOBACTERIUM LEPRAE; QUINOLINES; SKIN; TREATMENT OUTCOME.
|
|
| |
|
|
|
|
| |
|
|
| |
|
|
Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing.
by Kaplan, G;
Subject: GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INJECTIONS, INTRADERMAL; INJECTIONS, SUBCUTANEOUS; KERATINOCYTES; LANGERHANS CELLS; LEPROSY; RECOMBINANT PROTEINS; SKIN; WOUND HEALING; ADMINISTRATION & DOSAGE.
|
|
| |
|
|
|
|
| |
|
|
| |
|
|
The efficacy of a four-week, ofloxacin-containing regimen compared with standard who-mdt in PB leprosy.
by Balagon , MF;
Subject: DAPSONE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; LEPROSTATIC AGENTS; LEPROSY, PAUCIBACILLARY; OFLOXACIN; RECURRENCE; RIFAMPIN; SKIN; TIME FACTORS; TREATMENT OUTCOME; COMBINATION DRUG THERAPY.
|
|
| |
|
|
|
|
| |
|
|
| |
|
|
Prospective study of serological conversion as a risk factor for development of leprosy among household contacts.
by Klatser, PR;
Subject: ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; DISEASE TRANSMISSION, INFECTIOUS; FAMILY CHARACTERISTICS; GLYCOLIPIDS; INCIDENCE; LEPROSY; MYCOBACTERIUM LEPRAE; PROSPECTIVE STUDIES; RISK FACTORS; SEROLOGIC TESTS.
|
|
| |
|
|
|
|
| |
|
|
| |
|
|
Clinical and histological features of inoculation site skin lesions in cynomolgus monkeys experimentally infected with Orientia tsutsugamushi.
by Walsh , DS;
Subject: ANTIBODIES, BACTERIAL; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN G; INJECTIONS, INTRADERMAL; LYMPH NODES; LYMPHATIC DISEASES; MONKEY DISEASES; ORIENTIA TSUTSUGAMUSHI; PILOT PROJECTS; SCRUB TYPHUS; SKIN; MACACA FASCICULARIS.
|
|
| |
|
|
|
|
| |
|
|
| |
|
|
Controlled long-term therapy of leprosy with B663 (lamprene, clofazimine) compared with DDS.
by Tolentino, JG;
Subject: CLOFAZIMINE; DAPSONE; DRUG EVALUATION; DRUG RESISTANCE, MICROBIAL; DRUG TOLERANCE; ERYTHEMA NODOSUM; LEPROSY; SKIN PIGMENTATION; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL DRUG RESISTANCE.
|
|
| |
|
|
|
|
| |
|
|
| |
|
|
Controlled drug trial of B.663 compared with DDS. preliminary (48 week) report.
by Tolentino, JG;
Subject: ANILINE COMPOUNDS/THERAPEUTIC USE; DAPSONE; LEPROSY; NEURITIS; PHENAZINES; PHENYLAMINES; DAPSONE/ADMINISTRATION & DOSAGE; DAPSONE/ADVERSE EFFECTS; DAPSONE/THERAPEUTIC USE; LEPROSY/DRUG THERAPY; NEURITIS/CHEMICALLY INDUCED; PHENAZINES/ADMINISTRATION & DOSAGE; PHENAZINES/ADVERSE EFFECTS; PHENAZINES/THERAPEUTIC USE.
|
|
| |
|
|
|
|
| |
|
|
| |
|
|
Evaluation of polymerase chain reaction amplification of Mycobacterium leprae-specific repetitive sequence in biopsy specimens from leprosy patients.
by Kim, JD;
Subject: BASE SEQUENCE; BIOPSY; DNA, BACTERIAL; EVALUATION STUDIES AS TOPIC; LEPROSY; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM LEPRAE; POLYMERASE CHAIN REACTION; REPETITIVE SEQUENCES, NUCLEIC ACID; SENSITIVITY AND SPECIFICITY.
|
|
| |
|
|
|
|
| |
|
|
| « Previous 1 2 Next » |
